Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

Dispersion was extreme. MRNA led at +55.45% ($130.38 → $202.67), closing at $198.88 — 94.77% of its range — with a +42.10% period return. TEM followed at +48.06%, finishing 98.52% of its range at $85.01. At the other end, KPTI fell -39.95% ($2.07 → $1.24), and QURE (-27.76%) and CDXS (-25.07%) also shed a quarter or more of their value.

Implied volatility repeatedly mispriced the realized move. TEM was the biggest surprise at 3.74x realized/implied, with MRNA (3.58x), SYK (3.72x), AMGN (2.90x) and STIM (2.65x) also far exceeding what options priced. Notably, AMGN (41.71% realized vs. 28.16% implied) and SYK (34.78% vs. 30.11%) saw realized volatility outrun implied outright. The reverse held in the high-IV micro caps: DBVT (254.30% IV, 0.30x), CDXS (272.66% IV, 0.43x) and ADUS (0.62x) were priced for far more than they delivered.

Range closes skewed to the lows among decliners — CNC at 6.68%, ABT 8.83%, SYK 8.31%, QURE 9.82% — while gainers closed near highs.

Broader Market Context

Differential behavior within the sector. Although every name here is a Health Sector constituent, the group behaved less like a sector and more like a collection of separate markets. The spread from MRNA (+55.45%) to KPTI (-39.95%) is roughly 95 percentage points. Large-cap defensives clustered tightly and quietly: JNJ (-7.25%), ABBV (+9.17%), MRK (+7.90%), GILD (+7.88%) and LLY (+7.59%) all realized volatility near 20-25%, consistent with index-like behavior. Smaller, single-catalyst names — KPTI, CDXS, QURE, STIM, MGNX, DBVT — realized 49-114% volatility. That gap alone argues the period's action was driven by company-specific outcomes rather than a uniform sector bid.

Rotation versus idiosyncratic moves. The pattern does not look cleanly like rotation into or out of Health Sector as a block. A defensive rotation would typically lift the mega-cap pharma names together while sparing the speculative tail; instead, pharma was mixed (ABBV, MRK, GILD higher; BMY -11.20%, AMGN -16.01%) and XLV itself was only -5.37% with 14.94% realized volatility — the calmest reading in the set. Two sub-groups did move with some internal coherence, which is worth flagging:

• Managed care / payors were uniformly weak: UNH -9.97%, HUM -12.11%, CNC -12.04%, CI -9.34%, CVS -14.21%. Group-level pressure like this is more consistent with a shared cost or policy input than with five independent stories.
• Med-tech and devices also sagged — SYK -19.46%, ABT -12.13% — with SYK realizing more volatility than implied, a sign the move caught positioning offside.

Plausible drivers. Without asserting specifics, the payor weakness is consistent with ongoing reimbursement, utilization-trend or policy uncertainty that periodically repriced this group as a whole. The biotech tail's behavior — huge percentage moves on small dollar prices, with triple-digit implied volatility in DBVT, CDXS and QURE — is typical of binary clinical, regulatory or financing outcomes, and the fact that several *under*-delivered versus implied suggests options had been priced for events that resolved benignly or slipped. Conversely, outsized realized moves in MRNA and TEM likely reflect stock-specific catalysts rather than a sector-wide risk-on impulse.